;PMID: 8048063
;source_file_934.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..48] = [t:0..48]
;1)sentence:[e:54..183] = [t:54..183]
;2)section:[e:187..207] = [t:187..207]
;3)section:[e:211..300] = [t:211..300]
;4)sentence:[e:304..490] = [t:304..490]
;5)sentence:[e:491..755] = [t:491..755]
;6)sentence:[e:756..932] = [t:756..932]
;7)sentence:[e:933..1169] = [t:933..1169]
;8)sentence:[e:1170..1273] = [t:1170..1273]
;9)sentence:[e:1274..1393] = [t:1274..1393]
;10)sentence:[e:1394..1524] = [t:1394..1524]
;11)sentence:[e:1525..1615] = [t:1525..1615]
;12)sentence:[e:1616..1789] = [t:1616..1789]
;13)sentence:[e:1790..2093] = [t:1790..2093]
;14)section:[e:2097..2141] = [t:2097..2141]

;section 0 Span:0..48
;Toxicol Appl Pharmacol. 1994 Aug;127(2):199-208.
(SEC
  (FRAG (NNP:[0..7] Toxicol) (NNP:[8..12] Appl) (NNP:[13..22] Pharmacol)
        (.:[22..23] .) (CD:[24..28] 1994) (CC:[29..37] Aug;127-LRB-)
        (CD:[37..38] 2) (-RRB-:[38..39] -RRB-) (CD:[39..43] :199) (::[43..44] -)
        (CD:[44..47] 208) (.:[47..48] .)))

;sentence 1 Span:54..183
;Regulation of gene expression and acceleration of differentiation in human 
;keratinocytes by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
;[147..182]:substance:"2,3,7,8-tetrachlorodibenzo-p-dioxin"
(SENT
  (NP-HLN
    (NP
      (NP
        (NP (NN:[54..64] Regulation))
        (PP (IN:[65..67] of)
          (NP (NN:[68..72] gene) (NN:[73..83] expression))))
      (CC:[84..87] and)
      (NP
        (NP (NN:[88..100] acceleration))
        (PP (IN:[101..103] of)
          (NP (NN:[104..119] differentiation)))))
    (PP-LOC (IN:[120..122] in)
      (NP (JJ:[123..128] human) (NNS:[130..143] keratinocytes)))
    (PP (IN:[144..146] by)
      (NP (NN:[147..182] 2,3,7,8-tetrachlorodibenzo-p-dioxin)))
    (.:[182..183] .)))

;section 2 Span:187..207
;Gaido KW, Maness SC.
(SEC
  (FRAG (NNP:[187..192] Gaido) (NNP:[193..195] KW) (,:[195..196] ,)
        (NNP:[197..203] Maness) (NNP:[204..206] SC) (.:[206..207] .)))

;section 3 Span:211..300
;Chemical Industry Institute of Toxicology, Research Triangle Park, North 
;Carolina 27709.
(SEC
  (FRAG (NNP:[211..219] Chemical) (NNP:[220..228] Industry)
        (NNP:[229..238] Institute) (IN:[239..241] of)
        (NNP:[242..252] Toxicology) (,:[252..253] ,) (NNP:[254..262] Research)
        (NNP:[263..271] Triangle) (NNP:[272..276] Park) (,:[276..277] ,)
        (NNP:[278..283] North) (NNP:[285..293] Carolina) (.:[294..299] 27709)
        (.:[299..300] .)))

;sentence 4 Span:304..490
;2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a suspected human carcinogen, is 
;believed to produce its toxic and carcinogenic effects by altering expression
;of  growth-regulatory factors.
;[304..339]:substance:"2,3,7,8-Tetrachlorodibenzo-p-dioxin"
;[341..345]:substance:"TCDD"
;[366..376]:substance:"carcinogen"
(SENT
  (S
    (NP-SBJ-2
      (NP
        (NP (NN:[304..339] 2,3,7,8-Tetrachlorodibenzo-p-dioxin))
        (NP (-LRB-:[340..341] -LRB-) (NN:[341..345] TCDD)
            (-RRB-:[345..346] -RRB-)))
      (,:[346..347] ,)
      (NP (DT:[348..349] a) (VBN:[350..359] suspected) (JJ:[360..365] human)
          (NN:[366..376] carcinogen)))
    (,:[376..377] ,)
    (VP (VBZ:[378..380] is)
      (VP (VBN:[382..390] believed)
        (S
          (NP-SBJ-2 (-NONE-:[390..390] *))
          (VP (TO:[391..393] to)
            (VP (VB:[394..401] produce)
              (NP (PRP$:[402..405] its)
                (NML
                  (NML (JJ:[406..411] toxic)
                    (NML-1 (-NONE-:[411..411] *P*)))
                  (CC:[412..415] and)
                  (NML (JJ:[416..428] carcinogenic)
                    (NML-1 (NNS:[429..436] effects)))))
              (PP (IN:[437..439] by)
                (S-NOM-LGS
                  (NP-SBJ (-NONE-:[439..439] *))
                  (VP (VBG:[440..448] altering)
                    (NP
                      (NP (NN:[449..459] expression))
                      (PP (IN:[460..462] of)
                        (NP
                          (ADJP (NN:[464..470] growth) (HYPH:[470..471] -)
                                (JJ:[471..481] regulatory))
                          (NNS:[482..489] factors))))))))))))
    (.:[489..490] .)))

;sentence 5 Span:491..755
;TCDD alters the expression of a number of specific  genes in the transformed
;human keratinocyte cell line, SCC-12F, including  transforming growth
;factor-alpha (TGF-alpha), TGF-beta 2, plasminogen activator  inhibitor-2
;(PAI-2), and interleukin-1 beta (IL-1 beta).
;[491..495]:substance:"TCDD"
;[618..650]:substance:"transforming growth factor-alpha"
;[652..661]:substance:"TGF-alpha"
;[664..674]:substance:"TGF-beta 2"
;[676..710]:substance:"plasminogen activator  inhibitor-2"
;[712..717]:substance:"PAI-2"
;[724..742]:substance:"interleukin-1 beta"
;[744..753]:substance:"IL-1 beta"
(SENT
  (S
    (NP-SBJ (NN:[491..495] TCDD))
    (VP (VBZ:[496..502] alters)
      (NP
        (NP (DT:[503..506] the) (NN:[507..517] expression))
        (PP (IN:[518..520] of)
          (NP
            (NP (DT:[521..522] a) (NN:[523..529] number))
            (PP (IN:[530..532] of)
              (NP
                (NP (JJ:[533..541] specific) (NNS:[543..548] genes))
                (PP-LOC (IN:[549..551] in)
                  (NP
                    (NP (DT:[552..555] the) (VBN:[556..567] transformed)
                        (JJ:[568..573] human) (NN:[574..586] keratinocyte)
                        (NN:[587..591] cell) (NN:[592..596] line))
                    (,:[596..597] ,)
                    (NP (NN:[598..605] SCC-12F))))
                (,:[605..606] ,)
                (PP (VBG:[607..616] including)
                  (NP
                    (NP
                      (NP
                        (NML (VBG:[618..630] transforming)
                             (NN:[631..637] growth) (NN:[638..644] factor))
                        (HYPH:[644..645] -) (SYM:[645..650] alpha))
                      (NP (-LRB-:[651..652] -LRB-) (NN:[652..661] TGF-alpha)
                          (-RRB-:[661..662] -RRB-)))
                    (,:[662..663] ,)
                    (NP (NN:[664..672] TGF-beta) (CD:[673..674] 2))
                    (,:[674..675] ,)
                    (NP
                      (NP
                        (NML
                          (NML (NN:[676..687] plasminogen)
                               (NN:[688..697] activator))
                          (NN:[699..708] inhibitor))
                        (HYPH:[708..709] -) (CD:[709..710] 2))
                      (NP (NN:[711..712] -LRB-) (NN:[712..717] PAI-2)
                          (-RRB-:[717..718] -RRB-)))
                    (,:[718..719] ,) (CC:[720..723] and)
                    (NP
                      (NP (NN:[724..737] interleukin-1) (SYM:[738..742] beta))
                      (NP (-LRB-:[743..744] -LRB-)
                         (NN:[744..748] IL-1) (SYM:[749..753] beta)
                        (-RRB-:[753..754] -RRB-)))))))))))
    (.:[754..755] .)))

;sentence 6 Span:756..932
;To determine whether  nontransformed human keratinocytes (NHK) respond
;similarly to TCDD, we studied  the effect of TCDD on NHK growth and
;differentiation, and gene expression.
;[840..844]:substance:"TCDD"
;[872..876]:substance:"TCDD"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[756..756] *))
      (VP (TO:[756..758] To)
        (VP (VB:[759..768] determine)
          (SBAR (IN:[769..776] whether)
            (S
              (NP-SBJ
                (NP (JJ:[778..792] nontransformed) (JJ:[793..798] human)
                    (NNS:[799..812] keratinocytes))
                (NP (-LRB-:[813..814] -LRB-) (NN:[814..817] NHK)
                    (-RRB-:[817..818] -RRB-)))
              (VP (VBP:[819..826] respond)
                (ADVP-MNR (RB:[827..836] similarly))
                (PP-CLR (TO:[837..839] to)
                  (NP (NN:[840..844] TCDD)))))))))
    (,:[844..845] ,)
    (NP-SBJ-3 (PRP:[846..848] we))
    (VP (VBD:[849..856] studied)
      (NP
        (NP (DT:[858..861] the) (NN:[862..868] effect))
        (PP (IN:[869..871] of)
          (NP (NN:[872..876] TCDD)))
        (PP (IN:[877..879] on)
          (NP
            (NP
              (NP
                (NML-1 (NN:[880..883] NHK))
                (NN:[884..890] growth))
              (CC:[891..894] and)
              (NP
                (NML-1 (-NONE-:[894..894] *P*))
                (NN:[895..910] differentiation)))
            (,:[910..911] ,) (CC:[912..915] and)
            (NP (NN:[916..920] gene) (NN:[921..931] expression))))))
    (.:[931..932] .)))

;sentence 7 Span:933..1169
;NHK  were treated prior to reaching confluence with 10 nM TCDD and evaluated
;at 1, 2,  3, and 5 days following treatment for the effect of TCDD on cell
;number,  morphology, involucrin levels, mRNA expression, and protein
;concentrations.
;[985..987]:quantitative-value:"10"
;[988..990]:quantitative-units:"nM"
;[991..995]:substance:"TCDD"
;[1013..1014]:quantitative-value:"1"
;[1016..1017]:quantitative-value:"2"
;[1020..1021]:quantitative-value:"3"
;[1027..1028]:quantitative-value:"5"
;[1029..1033]:quantitative-units:"days"
;[1072..1076]:substance:"TCDD"
;[1125..1129]:substance:"mRNA"
;[1146..1153]:substance:"protein"
(SENT
  (S
    (NP-SBJ-2 (NN:[933..936] NHK))
    (VP (VBD:[938..942] were)
      (VP
        (VP (VBN:[943..950] treated)
          (NP-2 (-NONE-:[950..950] *))
          (PP-TMP (JJ:[951..956] prior)
            (PP (TO:[957..959] to)
              (S-NOM
                (NP-SBJ (-NONE-:[959..959] *))
                (VP (VBG:[960..968] reaching)
                  (NP
                    (NP (NN:[969..979] confluence))
                    (PP (IN:[980..984] with)
                      (NP
                        (NML (CD:[985..987] 10) (NN:[988..990] nM))
                        (NP (NN:[991..995] TCDD))))))))))
        (CC:[996..999] and)
        (VP (VBN:[1000..1009] evaluated)
          (NP-2 (-NONE-:[1009..1009] *))
          (PP-TMP (IN:[1010..1012] at)
            (NP
              (NP
                (NP (CD:[1013..1014] 1)
                  (NML-1 (-NONE-:[1014..1014] *P*)))
                (,:[1014..1015] ,)
                (NP (CD:[1016..1017] 2)
                  (NML-1 (-NONE-:[1017..1017] *P*)))
                (,:[1017..1018] ,)
                (NP (CD:[1020..1021] 3)
                  (NML-1 (-NONE-:[1021..1021] *P*)))
                (,:[1021..1022] ,) (CC:[1023..1026] and)
                (NP (CD:[1027..1028] 5)
                  (NML-1 (NNS:[1029..1033] days))))
              (PP (VBG:[1034..1043] following)
                (NP (NN:[1044..1053] treatment)))))
          (PP (IN:[1054..1057] for)
            (NP
              (NP (DT:[1058..1061] the) (NN:[1062..1068] effect))
              (PP (IN:[1069..1071] of)
                (NP (NN:[1072..1076] TCDD)))
              (PP (IN:[1077..1079] on)
                (NP
                  (NP (NN:[1080..1084] cell) (NN:[1085..1091] number))
                  (,:[1091..1092] ,)
                  (NP (NN:[1094..1104] morphology))
                  (,:[1104..1105] ,)
                  (NP (NN:[1106..1116] involucrin) (NNS:[1117..1123] levels))
                  (,:[1123..1124] ,)
                  (NP (NN:[1125..1129] mRNA) (NN:[1130..1140] expression))
                  (,:[1140..1141] ,) (CC:[1142..1145] and)
                  (NP (NN:[1146..1153] protein)
                      (NNS:[1154..1168] concentrations)))))))))
    (.:[1168..1169] .)))

;sentence 8 Span:1170..1273
;TCDD  altered both the mRNA and protein concentrations of TGF-alpha, TGF-beta
;2,  PAI-2, and IL-1 beta.
;[1170..1174]:substance:"TCDD"
;[1193..1197]:substance:"mRNA"
;[1202..1209]:substance:"protein"
;[1228..1237]:substance:"TGF-alpha"
;[1239..1249]:substance:"TGF-beta 2"
;[1252..1257]:substance:"PAI-2"
;[1263..1272]:substance:"IL-1 beta"
(SENT
  (S
    (NP-SBJ (NN:[1170..1174] TCDD))
    (VP (VBD:[1176..1183] altered)
      (NP
        (NP (CC:[1184..1188] both)
          (NP (DT:[1189..1192] the) (NN:[1193..1197] mRNA)
            (NML-1 (-NONE-:[1197..1197] *P*)))
          (CC:[1198..1201] and)
          (NP (NN:[1202..1209] protein)
            (NML-1 (NNS:[1210..1224] concentrations))))
        (PP (IN:[1225..1227] of)
          (NP
            (NP (NN:[1228..1237] TGF-alpha))
            (,:[1237..1238] ,)
            (NP (NN:[1239..1247] TGF-beta) (CD:[1248..1249] 2))
            (,:[1249..1250] ,)
            (NP (NN:[1252..1257] PAI-2))
            (,:[1257..1258] ,) (CC:[1259..1262] and)
            (NP (NN:[1263..1267] IL-1) (SYM:[1268..1272] beta))))))
    (.:[1272..1273] .)))

;sentence 9 Span:1274..1393
;The mRNA level for u-PA, a plasminogen activator that is  inhibited by PAI-2,
;was not altered following TCDD treatment.
;[1278..1282]:substance:"mRNA"
;[1293..1297]:substance:"u-PA"
;[1345..1350]:substance:"PAI-2"
;[1378..1382]:substance:"TCDD"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[1274..1277] The) (NN:[1278..1282] mRNA) (NN:[1283..1288] level))
      (PP (IN:[1289..1292] for)
        (NP
          (NP (NN:[1293..1297] u-PA))
          (,:[1297..1298] ,)
          (NP
            (NP (DT:[1299..1300] a) (NN:[1301..1312] plasminogen)
                (NN:[1313..1322] activator))
            (SBAR
              (WHNP-1 (WDT:[1323..1327] that))
              (S
                (NP-SBJ-1 (-NONE-:[1327..1327] *T*))
                (VP (VBZ:[1328..1330] is)
                  (VP (VBN:[1332..1341] inhibited)
                    (NP-1 (-NONE-:[1341..1341] *))
                    (PP (IN:[1342..1344] by)
                      (NP-LGS (NN:[1345..1350] PAI-2)))))))))))
    (,:[1350..1351] ,)
    (VP (VBD:[1352..1355] was) (RB:[1356..1359] not)
      (VP (VBN:[1360..1367] altered)
        (NP-2 (-NONE-:[1367..1367] *))
        (S-TMP
          (NP-SBJ (-NONE-:[1367..1367] *))
          (VP (VBG:[1368..1377] following)
            (NP (NN:[1378..1382] TCDD) (NN:[1383..1392] treatment))))))
    (.:[1392..1393] .)))

;sentence 10 Span:1394..1524
;However, u-PA  protein levels were significantly induced, indicating an
;effect of TCDD on u-PA  synthesis, secretion, or turnover.
;[1403..1407]:substance:"u-PA"
;[1409..1416]:substance:"protein"
;[1476..1480]:substance:"TCDD"
;[1484..1488]:substance:"u-PA"
(SENT
  (S
    (ADVP (RB:[1394..1401] However))
    (,:[1401..1402] ,)
    (NP-SBJ-2 (NN:[1403..1407] u-PA) (NN:[1409..1416] protein)
              (NNS:[1417..1423] levels))
    (VP (VBD:[1424..1428] were)
      (ADVP-MNR (RB:[1429..1442] significantly))
      (VP (VBN:[1443..1450] induced)
        (NP-2 (-NONE-:[1450..1450] *))
        (,:[1450..1451] ,)
        (S-MNR
          (NP-SBJ (-NONE-:[1451..1451] *))
          (VP (VBG:[1452..1462] indicating)
            (NP
              (NP (DT:[1463..1465] an) (NN:[1466..1472] effect))
              (PP (IN:[1473..1475] of)
                (NP (NN:[1476..1480] TCDD)))
              (PP (IN:[1481..1483] on)
                (NP
                  (NP
                    (NML-1 (NN:[1484..1488] u-PA))
                    (NN:[1490..1499] synthesis))
                  (,:[1499..1500] ,)
                  (NP
                    (NML-1 (-NONE-:[1500..1500] *P*))
                    (NN:[1501..1510] secretion))
                  (,:[1510..1511] ,) (CC:[1512..1514] or)
                  (NP
                    (NML-1 (-NONE-:[1514..1514] *P*))
                    (NN:[1515..1523] turnover)))))))))
    (.:[1523..1524] .)))

;sentence 11 Span:1525..1615
;TCDD enhanced NHK differentiation, as  determined by an increase in
;involucrin expression.
;[1525..1529]:substance:"TCDD"
;[1593..1603]:substance:"involucrin"
(SENT
  (S
    (NP-SBJ (NN:[1525..1529] TCDD))
    (VP (VBD:[1530..1538] enhanced)
      (NP (NN:[1539..1542] NHK) (NN:[1543..1558] differentiation))
      (,:[1558..1559] ,)
      (PP (IN:[1560..1562] as)
        (S-NOM
          (NP-SBJ-1 (-NONE-:[1562..1562] *))
          (VP (VBN:[1564..1574] determined)
            (NP-1 (-NONE-:[1574..1574] *))
            (PP (IN:[1575..1577] by)
              (NP
                (NP (DT:[1578..1580] an) (NN:[1581..1589] increase))
                (PP (IN:[1590..1592] in)
                  (NP (NN:[1593..1603] involucrin) (NN:[1604..1614] expression)))))))))
    (.:[1614..1615] .)))

;sentence 12 Span:1616..1789
;TCDD did not alter cell  number or colony-forming efficiency, suggesting that
;TCDD was enhancing the  differentiation of cells already committed to
;terminal differentiation.
;[1616..1620]:substance:"TCDD"
;[1694..1698]:substance:"TCDD"
(SENT
  (S
    (NP-SBJ (NN:[1616..1620] TCDD))
    (VP (VBD:[1621..1624] did) (RB:[1625..1628] not)
      (VP (VB:[1629..1634] alter)
        (NP
          (NP (NN:[1635..1639] cell) (NN:[1641..1647] number))
          (CC:[1648..1650] or)
          (NP
            (ADJP (NN:[1651..1657] colony) (HYPH:[1657..1658] -)
                  (VBG:[1658..1665] forming))
            (NN:[1666..1676] efficiency)))
        (,:[1676..1677] ,)
        (S-MNR
          (NP-SBJ (-NONE-:[1677..1677] *))
          (VP (VBG:[1678..1688] suggesting)
            (SBAR (IN:[1689..1693] that)
              (S
                (NP-SBJ (NN:[1694..1698] TCDD))
                (VP (VBD:[1699..1702] was)
                  (VP (VBG:[1703..1712] enhancing)
                    (NP
                      (NP (DT:[1713..1716] the)
                          (NN:[1718..1733] differentiation))
                      (PP (IN:[1734..1736] of)
                        (NP
                          (NP (NNS:[1737..1742] cells))
                          (VP
                            (ADVP-TMP (RB:[1743..1750] already))
                            (VBN:[1751..1760] committed)
                            (NP (-NONE-:[1760..1760] *))
                            (PP-CLR (TO:[1761..1763] to)
                              (NP (JJ:[1764..1772] terminal)
                                  (NN:[1773..1788] differentiation)))))))))))))))
    (.:[1788..1789] .)))

;sentence 13 Span:1790..2093
;These  results demonstrate that treatment of NHK with TCDD results in the
;simultaneous  modulation of expression of a number of growth-regulatory
;proteins and suggest  that the growth and differentiation response of human
;keratinocytes to TCDD is  due to a complex interaction of these diverse
;proteins.
;[1844..1848]:substance:"TCDD"
;[1936..1944]:substance:"proteins"
;[2029..2033]:substance:"TCDD"
;[2084..2092]:substance:"proteins"
(SENT
  (S
    (NP-SBJ (DT:[1790..1795] These) (NNS:[1797..1804] results))
    (VP
      (VP (VBP:[1805..1816] demonstrate)
        (SBAR (IN:[1817..1821] that)
          (S
            (NP-SBJ
              (NP (NN:[1822..1831] treatment))
              (PP (IN:[1832..1834] of)
                (NP (NN:[1835..1838] NHK)))
              (PP (IN:[1839..1843] with)
                (NP (NN:[1844..1848] TCDD))))
            (VP (VBZ:[1849..1856] results)
              (PP-CLR (IN:[1857..1859] in)
                (NP
                  (NP (DT:[1860..1863] the) (JJ:[1864..1876] simultaneous)
                      (NN:[1878..1888] modulation))
                  (PP (IN:[1889..1891] of)
                    (NP
                      (NP (NN:[1892..1902] expression))
                      (PP (IN:[1903..1905] of)
                        (NP
                          (NP (DT:[1906..1907] a) (NN:[1908..1914] number))
                          (PP (IN:[1915..1917] of)
                            (NP
                              (ADJP (NN:[1918..1924] growth)
                                    (HYPH:[1924..1925] -)
                                    (JJ:[1925..1935] regulatory))
                              (NNS:[1936..1944] proteins)))))))))))))
      (CC:[1945..1948] and)
      (VP (VBP:[1949..1956] suggest)
        (SBAR (IN:[1958..1962] that)
          (S
            (NP-SBJ
              (NP (DT:[1963..1966] the)
                (NML (NN:[1967..1973] growth) (CC:[1974..1977] and)
                     (NN:[1978..1993] differentiation))
                (NN:[1994..2002] response))
              (PP (IN:[2003..2005] of)
                (NP (JJ:[2006..2011] human) (NNS:[2012..2025] keratinocytes)))
              (PP (TO:[2026..2028] to)
                (NP (NN:[2029..2033] TCDD))))
            (VP (VBZ:[2034..2036] is)
              (PP-PRD (IN:[2038..2041] due)
                (PP (TO:[2042..2044] to)
                  (NP
                    (NP (DT:[2045..2046] a) (JJ:[2047..2054] complex)
                        (NN:[2055..2066] interaction))
                    (PP (IN:[2067..2069] of)
                      (NP (DT:[2070..2075] these) (JJ:[2076..2083] diverse)
                          (NNS:[2084..2092] proteins)))))))))))
    (.:[2092..2093] .)))

;section 14 Span:2097..2141
;PMID: 8048063 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2097..2101] PMID) (::[2101..2102] :) (CD:[2103..2110] 8048063)
        (NN:[2111..2112] -LSB-) (NNP:[2112..2118] PubMed) (::[2119..2120] -)
        (NN:[2121..2128] indexed) (IN:[2129..2132] for)
        (NNP:[2133..2141] MEDLINE-RSB-)))
